-
BiomX's Acne Vulgaris Treatment Fails To Top Vehicle Treatment Cohort
Monday, October 18, 2021 - 5:48pm | 231Read More...BiomX Inc (NYSE: PHGE) announced results from its Phase 2 study to assess BX001 to improve the appearance of skin in acne-prone subjects. A statistically significant improvement from baseline was observed in the appearance of acne-prone skin, but no meaningful difference was...
-
Sol-Gel Wins FDA Approval For Fixed-Dose Combination Of Tretinoin, Benzoyl Peroxide For Acne Vulgaris
Tuesday, July 27, 2021 - 10:26am | 240Read More...The FDA has approved Sol-Gel Technologies Ltd's (NASDAQ: SLGL) first proprietary drug product, Twyneo (tretinoin/benzoyl peroxide) cream, 0.1%/3%, indicated for acne vulgaris in adults and pediatric patients nine years of age and older. Twyneo uses Sol-Gel's patented...
